Home › NDC Lookup › RxCUI directory › RxCUI 199147

Lamivudine 150 MG Oral Tablet — RxCUI 199147

RxNorm drug concept · Semantic clinical drug
RxCUI 199147 Semantic clinical drug · SCD ● Current RxNorm concept 21 FDA products 30 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI199147
Official nameLamivudine 150 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known as3TC 150 MG Oral Tablet
FDA products mapped21
Package NDCs mapped30
Reported Medicaid activity (SDUD)2,774 prescriptions · 23 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lamivudine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lamivudine treats HIV-1 infection when combined with other HIV medicines. A separate lower-dose tablet treats chronic hepatitis B. Make sure you have the version your doctor prescr...
  • For HIV-1 it is taken by mouth once or twice daily, with or without food. Follow your prescriber's schedule exactly. Children's doses depend on weight.
  • Common ones are headache, nausea, tiredness, stuffy nose, diarrhea and cough. Call your doctor if you notice signs of liver problems, pancreatitis, or an allergic reaction.
  • Please don't stop on your own. If you also have hepatitis B, stopping can cause a serious flare-up, and your liver needs close monitoring afterward. Talk to your doctor first.
📖 Read our full Lamivudine guide →

🕸️ Concept Web — How Lamivudine 150 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lamivudine 150 MG Oral Tablet RxCUI 199147

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lamivudine 68244
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Epivir 196478
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lamivudine Oral Tablet 372563
    • Lamivudine Oral Product 1162819
    • Lamivudine Pill 1162820
    • Lamivudine Oral Tablet [Epivir] 367794
    • Epivir Oral Product 1167630
    • Epivir Pill 1167631
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lamivudine 150 MG SCDC · 316127
  • Lamivudine Oral Tablet SCDF · 372563
  • Lamivudine Oral Product SCDG · 1162819
  • Lamivudine Pill SCDG · 1162820

Brand-Name Concepts

  • Lamivudine 150 MG Oral Tablet [Epivir] SBD · 152931
  • Lamivudine 150 MG [Epivir] SBDC · 565111
  • Lamivudine Oral Tablet [Epivir] SBDF · 367794
  • Epivir Oral Product SBDG · 1167630
  • Epivir Pill SBDG · 1167631
  • Epivir BN · 196478

📦 FDA Products & Package NDCs

21 products · 30 package NDCs
30 package NDCs map to RxCUI 199147 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00904-6583-04 30 BLISTER PACK in 1 CARTON (0904-6583-04) / 1 TABLET, FILM... LAMIVUDINE Major Pharmaceuticals 2011-12-02
31722-0753-06 600 TABLET, FILM COATED in 1 BOTTLE (31722-753-06) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0753-31 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-753-31) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0753-32 100 TABLET, FILM COATED in 1 CARTON (31722-753-32) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0753-60 60 TABLET, FILM COATED in 1 BOTTLE (31722-753-60) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0754-06 600 TABLET, FILM COATED in 1 BOTTLE (31722-754-06) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0754-30 30 TABLET, FILM COATED in 1 BOTTLE (31722-754-30) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0754-31 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-754-31) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
31722-0754-32 100 TABLET, FILM COATED in 1 CARTON (31722-754-32) Lamivudine Camber Pharmaceuticals, Inc. 2014-01-06
33342-0001-09 60 TABLET, FILM COATED in 1 BOTTLE (33342-001-09) Lamivudine Macleods Pharmaceuticals Limited 2019-05-02
33342-0002-07 30 TABLET, FILM COATED in 1 BOTTLE (33342-002-07) Lamivudine Macleods Pharmaceuticals Limited 2019-05-02
49702-0203-18 60 TABLET, FILM COATED in 1 BOTTLE (49702-203-18) EPIVIR ViiV Healthcare Company 2010-10-04
49702-0204-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-204-13) EPIVIR ViiV Healthcare Company 2010-10-04
49702-0205-48 240 mL in 1 BOTTLE (49702-205-48) EPIVIR ViiV Healthcare Company 2010-10-04
50742-0623-60 60 TABLET in 1 BOTTLE, PLASTIC (50742-623-60) Lamivudine Ingenus Pharmaceuticals, LLC 2017-02-01
50742-0624-60 30 TABLET in 1 BOTTLE, PLASTIC (50742-624-60) Lamivudine Ingenus Pharmaceuticals, LLC 2017-02-01
60429-0353-60 60 TABLET, FILM COATED in 1 BOTTLE (60429-353-60) LAMIVUDINE Golden State Medical Supply, Inc. 2011-12-02
60429-0354-30 30 TABLET, FILM COATED in 1 BOTTLE (60429-354-30) LAMIVUDINE Golden State Medical Supply, Inc. 2011-12-02
60505-3251-06 60 TABLET, FILM COATED in 1 BOTTLE (60505-3251-6) LAMIVUDINE Apotex Corp. 2011-12-02
60505-3251-08 1000 TABLET, FILM COATED in 1 BOTTLE (60505-3251-8) LAMIVUDINE Apotex Corp. 2011-12-02
60505-3252-03 30 TABLET, FILM COATED in 1 BOTTLE (60505-3252-3) LAMIVUDINE Apotex Corp. 2011-12-02
60505-3252-08 1000 TABLET, FILM COATED in 1 BOTTLE (60505-3252-8) LAMIVUDINE Apotex Corp. 2011-12-02
60687-0720-21 30 BLISTER PACK in 1 CARTON (60687-720-21) / 1 TABLET, FILM... Lamivudine American Health Packaging 2023-01-19
64380-0710-03 60 TABLET, FILM COATED in 1 BOTTLE (64380-710-03) Lamivudine Strides Pharma Science Limited 2018-10-19
64380-0711-04 30 TABLET, FILM COATED in 1 BOTTLE (64380-711-04) Lamivudine Strides Pharma Science Limited 2018-10-19
65862-0025-10 6 BLISTER PACK in 1 CARTON (65862-025-10) / 10 TABLET, FILM... Lamivudine Aurobindo Pharma Limited 2016-11-21
65862-0025-60 60 TABLET, FILM COATED in 1 BOTTLE (65862-025-60) Lamivudine Aurobindo Pharma Limited 2016-11-21
65862-0026-10 3 BLISTER PACK in 1 CARTON (65862-026-10) / 10 TABLET, FILM... Lamivudine Aurobindo Pharma Limited 2016-11-21
65862-0026-30 30 TABLET, FILM COATED in 1 BOTTLE (65862-026-30) Lamivudine Aurobindo Pharma Limited 2016-11-21
67046-1459-03 30 TABLET, FILM COATED in 1 BLISTER PACK (67046-1459-3) Lamivudine Coupler LLC 2025-02-06
Observed labelers: Camber Pharmaceuticals, Inc. (8) · Apotex Corp. (4) · Aurobindo Pharma Limited (4) · ViiV Healthcare Company (3) · Golden State Medical Supply, Inc. (2) · Ingenus Pharmaceuticals, LLC (2) · +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.